Get it on Google Play

Immix Biopharma receives FDA breakthrough therapy designation for NXC-201

January 28, 2026 8:45 AM EST Send to a Friend
Immix Biopharma Inc. (NASDAQ: IMMX) announced the U.S. Food and Drug Administration granted breakthrough therapy designation to its treatment NXC-201 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login